Scientific Papers

Enteric glia as a player of gut-brain interactions during Parkinson’s disease


1. Introduction

Parkinson’s disease (PD) is a neurodegenerative disorder that affects multiple systems. An avenue of scientific and clinical evidence brought rise to the interplay between the central nervous system (CNS) and the gastrointestinal (GI) tract, revealing what we know as the gut-brain axis. It is known that patients with PD present a range of GI pathological manifestations such as chronic constipation (affecting ~80% of patients with gastrointestinal symptoms), abdominal pain, and other signs of disorders of gut-brain interaction (DGBI) that can be present before any classic motor symptom (Travagli et al., 2020; Moudgal et al., 2021). Several groups have postulated theories for the pathogenesis of PD and, in an attempt to define a beginning, the truth is that today we have evidence to understand PD as a highly heterogeneous pathology that must involve different neuroinflammatory and neurodegenerative pathways (Leclair-Visonneau et al., 2020; Rolli-Derkinderen et al., 2020). Even subtypes of PD (body-first or brain-first) based on clinical and post-mortem evaluation have been proposed (Borghammer et al., 2022). In both ways, the gut-brain axis is recurrently described as an integral part of the PD, and a pathway that connects the different areas of the body where the disease manifests itself (Chen and Lin, 2022; Tan et al., 2022). This axis is subject to enormous modulation given the diversity of signaling at the level of the GI tract and the enteric nervous system (ENS; Carabotti et al., 2015). In the last years, a complex interaction between epithelial, neural, immunological, and microbial components emerged as critical factors in the pathology of PD.

In the GI tract, enteric glia play multiple functions and are recognized for their crucial role in GI physiology (D’Antongiovanni et al., 2023). These specialized cells of the ENS maintain intestinal homeostasis through crosstalk with various enteric cell types such as neuronal, epithelial, immune, and endocrine cells. The perception and modulation of the gut environment by enteric glia is based on a distinct transcriptional signature among glial types, which, associated with its morphological and locational diversity, makes enteric glia a unique glial type (Rosenberg and Rao, 2021). These cells are directly related to pathological conditions, such as DGBI, acting on the physiopathology of gut inflammation, dysmotility, and abdominal pain processes – known features of PD (Seguella et al., 2019; Lucarini et al., 2021; Rosenberg and Rao, 2021; Seguella and Gulbransen, 2021). In addition, evidence suggests that enteric glia are sensitive to gut microbiota and then contribute to gut-brain communication via microbial signaling pathways (Seguella et al., 2023). Treatments with commensal microbiota in animal models of PD have been shown to improve conditions associated with PD pathology, so the understanding of its interactions and mechanisms is fundamental.

This review aims to demonstrate the potential roles of enteric glia in the gut-brain axis in PD. Here, we give special attention to enteric glia phenotypes associated with glial neuroimmune modulation and inflammation, how glial and/or microbial molecules can affect each other, impacting gut dynamics, and the role of enteric glia in enteric neurotransmission, dysmotility, and visceral hypersensitivity. All these aspects, at different stages of the disease, likely contribute to the development and/or progression of PD and significantly impact patient quality of life. We gathered clinical data and animal models of PD, using different approaches, which allowed us to discuss and propose classic and new ideas to treat PD based on glial signaling.

2. Neuroinflammation through the gut-brain axis in Parkinson’s disease: the role of enteric glia

PD is a neuroinflammatory disorder in which inflammation has a key role in the neurodegenerative response (Tansey et al., 2022). Considering this, the interaction between gut neural and immune cells may contribute to generating the peripheral inflammatory response. Additionally, a complex enteric neuro-glial network participates in immune response modulation (Schneider et al., 2022). Studies have highlighted the gut condition in PD, in both patients and experimental models, suggesting it is a target for disease intervention and a source of pathologic/inflammatory signs related to PD pathogenesis (Travagli et al., 2020). Accordingly, it is well known that inflammatory bowel disease (IBDs) patients are at risk for PD (Lee et al., 2021; Li et al., 2023). Breakdown of the intestinal epithelial barrier (IEB) and gut inflammation has been described during PD, along with the changes in the enteric neurochemical code and enteric glial reactivity (Clairembault et al., 2014, 2015; Corbille et al., 2016; Coletto et al., 2021; Thomasi et al., 2022). Therefore, regardless of whether PD originates bottom-up or top-down through the gut-brain axis, peripheral neuroinflammatory responses are known to be associated with the disorder. There is ongoing debate regarding the role of peripheral neuroinflammation in promoting or exacerbating PD pathology through the gut-brain axis. Some reports show that intestinal inflammation induces and exacerbates neuroinflammation and dopaminergic neurodegeneration in CNS with or without detectable Lewy pathology (Garrido-Gil et al., 2018; Kishimoto et al., 2019; Lin et al., 2022). In this frame, the role of glial cells has been appreciated in the last decade and specifically enteric glia gained a starring role in the intestinal inflammatory scenario in PD as a key neuroimmune element.

Enteric glia is widely distributed throughout the GI tract, found in all layers, mucosal, submucosal/myenteric plexus, and muscular layers, and plays critical site-specific functions, essential for tissue physiology. Along with its original role of providing trophic supply to neurons, enteric glia is necessary for maintaining intestinal epithelium homeostasis, modulating intestinal motility, neurotransmission, and immune response (Gulbransen et al., 2012; McClain et al., 2014, 2015; Delvalle et al., 2018b; Grubisic et al., 2020; Ahmadzai et al., 2021; Seguella and Gulbransen, 2021). In PD, these functions are disrupted (Devos et al., 2013; Clairembault et al., 2014, 2015) and appear together with enteric glial reactivity, a hallmark of neuroinflammation. Evaluation of samples obtained by colonoscopy from patients with PD shows an association between the presence of reactive enteric gliosis, identified by the increase in glial markers glial fibrillar acidic protein (GFAP) and Sox10, together with the increase in proinflammatory cytokines such as IL-6, TNF-α, IFN-γ, IL-1β, and chemokines as CCL2 and CCL5 (Devos et al., 2013; Perez-Pardo et al., 2019). Such alterations contribute to impaired IEB integrity and increased permeability observed in individuals with PD (Forsyth et al., 2011; Perez-Pardo et al., 2019).

Animal models of PD have been very useful in demonstrating the participation of the gut-brain axis and postulating temporal–spatial characteristics and mechanisms. In other words, checking areas of the nervous system as well as layer-specific responses in the intestine and their possible interactions. Multiple groups have demonstrated that enteric glia is activated in the myenteric plexus in several types of animal models of PD, whether bottom-up or top-down models (Perez-Pardo et al., 2019; Dodiya et al., 2020; Pellegrini et al., 2020, 2022; Palanisamy et al., 2022; Thomasi et al., 2022). The bottom-up (or body-first) hypothesis postulates the body periphery, mainly the ENS, as the first site of pathologic processes that would be spread out until CNS via inflammatory and anatomical pathways as it progresses. In contrast, the top-down theory (or brain-first) says the genesis of PD would start in some areas of the CNS and then reach the body periphery (Borghammer and Berge, 2019; Borghammer et al., 2022). Although there are no detailed descriptions of the pathway that reverberates pathological signals from one pathogenic site to the other, some have been postulated to be happening through peripheral nerves, such as the vagus nerve (Anselmi et al., 2017; Nanni and Travagli, 2020). Our group recently demonstrated that enteric glial reactivity occurs quickly and early in a top-down mouse model of PD (Thomasi et al., 2022). Within the colonic neuromuscular compartment, only 48 h after injury by 6-hydroxydopamine (6-OHDA), we observed a rise in GFAP content. This was followed by histological markers of inflammation, an increase in mucosal TNF-α, and changes to the tight junction protein occludin (Thomasi et al., 2022). In addition, higher immunolabeling of GFAP in the mucosal layer was verified in the PD model 1 week after neurodegeneration induction (Thomasi et al., 2022). These findings highlight the early role of enteric glia in gut neuroinflammation induced by central neurodegeneration. This is in accordance with data in patients showing that colonic inflammation and glial pathologic recruitment are probably higher at the beginning of the disease course, so early events can be associated with GI (such as constipation) and CNS symptoms (like anosmia, sleep disturbances, mood disorders) development. In accordance, gut barrier sensitization, which is also an early pathologic event in PD (Pellegrini et al., 2022), is commonly verified in parallel to a higher permeability in the blood–brain barrier. This last one promotes microgliosis, damage to central neurons, and systemic inflammation set (Chen and Lin, 2022). Interestingly, GI and CNS symptoms such as constipation, depression, and sleep disturbances can appear years before advanced neurodegenerative processes in the CNS—which highlights the pre-motor phase. Low-grade inflammation is hypothesized as a current process that can underlie the prodromal phase of PD (Houser and Tansey, 2017; Rolli-Derkinderen et al., 2020).

Another relevant enteric glia feature is their immunocompetence since it can respond to damage through the activation of Toll-like receptors (TLR) like TLR2 and TLR4 (Turco et al., 2014). These same receptors are altered in PD, whether in the CNS or ENS and likely contribute to the early intestinal pathology identified in PD (Gorecki et al., 2021; Zhang et al., 2023). Moreover, enteric glia express MHC class II molecules, enabling communication with cells of the innate and adaptive immune systems (Da Silveira et al., 2011; Turco et al., 2014). Thus, enteric glia can detect signals present in the intestinal environment caused by the breakdown of the IEB. These signals can include microorganisms and microbial products, but also proinflammatory cytokines and neurotransmitters that bind to their receptors on enteric glia. In turn, enteric glia release proinflammatory cytokines, chemokines, and gliotransmitters like ATP, which contribute to the inflammatory response and neuronal damage (Chow and Gulbransen, 2017; Seguella and Gulbransen, 2021). Altogether, research about enteric glia during PD points to a clear relation with peripheral inflammation in PD, and this may favor the establishment of a general inflamed environment. Peripheric signaling likely reaches CNS through immune pathways and/or neuroglial signaling, and in both scenarios, enteric glia have quite a protagonism in the early phase of PD by their early reactive phenotype.

3. Enteric glia as a sensor of the gut microbiome

The gut-brain axis is considered an integral part of the PD pathophysiological processes, as demonstrated through several animal models and clinical correlations in patients (Blandini et al., 2009; Pellegrini et al., 2016a,b; Morais et al., 2018; Perez-Pardo et al., 2018; Dodiya et al., 2020; Nanni and Travagli, 2020; Thomasi et al., 2022; Xing et al., 2023). In addition, the intestinal microbiota is an important modulator of gut-brain signaling. It presents itself in dysbiosis, that is, an imbalance due to the reduction of beneficial commensal bacteria and alteration of their microbial metabolites such as short-chain fatty acids (SCFA) and lipopolysaccharide (LPS; Huang et al., 2023; Zhang et al., 2023). Due to the leaky gut condition, the ENS is exposed to pathological stimuli from the microbiota which may contribute to synucleinopathy, an alteration in α-synuclein metabolism that generates intracellular aggregates named Lewy bodies (Fitzgerald et al., 2019). Lewy bodies have been described both in the mucosal lamina propria and submucosal plexus (Wakabayashi et al., 1988; Corbille et al., 2016). However, which signaling pathways and cellular interactions are under this pathogenesis still needs to be better understood. In the last years, glia-microbe interactions have been addressed and defects in this signaling, as supposed to occur during PD, may drive ENS and CNS neuroimmune plasticity impacting neural function.

The mucosal enteric glia are in contact with multiple cell types such as immune-effector cells, enteroendocrine cells, blood vessels, and epithelium, thus performing intercellular communication in an integrative way that is critical for mucosal homeostasis (Bohorquez et al., 2014). This glial population is strongly influenced by microbiota, as mice treated with antibiotics and germ-free mice show mucosal glia depletion (Kabouridis et al., 2015). To understand the mechanism of this interaction, transgenic mice for fate-mapping show a new pool of enteric glia is recruited to the mucosal plexus from the myenteric ganglia, so the global enteric glia dynamic is sensitive to microbiota signaling (Kabouridis et al., 2015). This glial replenishment dynamic has been tested using human mucosal enteric glial cells xenografted in immune-compromised mice but it did not show dependence on the microbiome when tested through antibiotic treatment (Inlender et al., 2021). However, this has not been tested during inflammation or PD models, which provoke enteric glia reactivity and epithelial modifications in the gut barrier, as previously mentioned. The glial network of the mucosa closely regulates the intestinal epithelium, mainly in pathological conditions (Cheadle et al., 2014; Langness et al., 2017; Grubišić et al., 2022; Prochera and Rao, 2023), and in vitro studies demonstrate the glioprotective capacity on the intestinal epithelium via glia-derived s-nitrosoglutathione against acute exposure to bacterial pathogens (Flamant et al., 2011). S-nitrosoglutathione is a modulator of barrier function, mainly during inflammation, reinforcing tight junction function and integrity (Savidge et al., 2007; Flamant et al., 2011). Therefore, glia-driven effects due to microbial signaling may form a loop in the pro-inflammatory environment described in the mucosal layer of PD patients that accounts for intestinal epithelial plasticity.

The ability of the microbiota to drive glial plasticity adds complexity to Parkinsonian gut processes since profound modifications in the intestinal biofilm may be based on neuroimmune interactions established in the gut. Several microbial products, such as LPS and SCFA, could be candidates to promote signaling pathways associated with inflammation and cell metabolism, and those have been altered in patients with PD (Keshavarzian et al., 2015; He et al., 2020; Metzdorf and Tönges, 2021). When subjected to LPS treatment, a well-known damage-associated molecular pattern, enteric glia exert similar antigen-presenting cell features as MHC-II, CD86, glial derived neurotrophic factor (GDNF), TLR-2, and TNF-α expression (Yang H. et al., 2022). As mentioned, TLR signaling by activation of enteric glia can be a critical mechanism to integrate microbial signaling into ENS function (Gorecki et al., 2021). Interestingly, the glial protein S100B also comprises a signaling pathway that integrates glial TLR activity leading to NO release, an inhibitory neurotransmitter relevant to neuroglial interaction, motility, and inflammatory processes (Turco et al., 2014; Thomasi and Gulbransen, 2023). Seguella and colleagues argue that this glial signaling could be a defense response against bacterial bioproducts and pathogenic bacteria based on the acquisition of a glial pro-inflammatory profile that would collaborate for ENS dysfunction, inflammation, and dysbiotic reinforcement (Seguella et al., 2023). Both S100B and NO are molecules implicated in central and enteric neuroplasticity during PD (Colucci et al., 2012; Pellegrini et al., 2016a; Sampath et al., 2019; Angelopoulou et al., 2021; Kim et al., 2023). This TLR-S100B pathway has enormous modulatory potential for enteric function, mainly in the neuroimmune interactions established by enteric glia.

Bidirectionally, enteric glia is associated with microbial diversity based on structural domains of S100B (EF-hand calcium-binding and S100) and its protein domains. Interestingly, normal S100B condition and inhibition of its active or binding domain produce opposing effects on microbial diversity (Romano et al., 2021; Spica et al., 2023). Surprisingly, this work shows that distinct concentrations of S100B are associated with different microbial clusters. An in silico approach applying bioinformatics also indicated that the microbiota of healthy individuals and patients with IBDs might interact differentially with the multiple domains of S100B (Orsini et al., 2020). Then, they propose S100B as a candidate signaling molecule in the gut able to change microbial dynamics. Evidence from a unique cohort of PD patients shows that while mRNA of GFAP and Sox10 are upregulated in the colon, the levels of S100B are not modified (Devos et al., 2013). However, the gliotic profile that enteric glia assume during colonic inflammation in PD may also contribute to distinct protein–protein interactions and downstream signaling. S100B polymorphisms and their contributions to the pathogenesis of PD are widely described and tested at the CNS level (Angelopoulou et al., 2021) and, given the gut-brain axis, theories of genesis and propagation of the disease and glial signaling in the axis (Esposito et al., 2017; Borghammer and Berge, 2019; Leclair-Visonneau et al., 2020; Horsager et al., 2022), it is necessary to deepen the evaluation of enteric S100B.

Among the changes in the microbiome during PD, the variation of the Bifidobacterium, Lactobacillus, and Akkermansia genera stands out—being those recognized genera by the SCFA production (Romano et al., 2021). Studies with the reintroduction of SCFAs as butyrate or propionate in different animal models of PD demonstrate significant improvements in motor and cognitive deficits and IEB permeability (Kakoty et al., 2021; Liu et al., 2022). Bifidobacterium genus especially appears to impose an immune regulation on enteric glia that is variable among bacteria of this genus (Yang Y. et al., 2022). Both act on enteric glia to constrain or promote inflammation through receptor and neurotrophic factor modulation (Yang et al., 2020; Yang H. et al., 2022). Meanwhile, enteric glial responsiveness to SCFA may come from transporters and receptors activity and it seems that butyrate relies on glial internalization to activate the phosphokinase C (PKC) pathway (Defries and Beltran, 2020). Glial PKC in the gut is related to the capacitive feature of enteric glia that in turn evokes glial network and neuroglial communication (Sarosi et al., 1998). Bifidobacterium has also been correlated to improving the IEB by tight junctions modulation—a probiotic-based therapy proposed for PD patients (Tan et al., 2021; Di Vito et al., 2022). Interestingly, Bifidobacterium animalis can regulate GFAP and GDNF, glial proteins associated with the state of the IEB (Liu et al., 2022). In parallel, when treated with distinct Bifidobacterium species, the MPTP animal model of PD improved the CNS oxidative stress condition, protected the gut barrier, and suppressed the glial hyperactivation state (Li et al., 2022). This data demonstrates a clear connection between glial “immune” status with outcomes on microbiota and glial network that can ameliorate pro-inflammatory aspects of the gut-brain axis in PD.

4. The potential contribution of glial signaling in constipation and abdominal pain during Parkinson’s disease

Non-motor symptoms of PD include other dysfunctions that are credited to the primary condition of constipation, such as abdominal pain (Skjærbæk et al., 2021). Constipation is primarily a neuromuscular dysfunction involving impaired enteric neural signaling leading to slowing and/or incoordination of bowel movements (Metta et al., 2021). This dysfunctional pattern is described as a moderate sensitivity sign for future PD development (Mahlknecht et al., 2015). 28%–80% of PD patients experience constipation at some point in the pathological course (Klingelhoefer and Reichmann, 2017; Carrasco et al., 2018). Inflammation causes dysfunctions of the GI tract that, in the context of PD, have been associated with the genesis of constipation and pain.

In the last decade, several works in the field of Neurogastroenterology have demonstrated enteric glia as a modulator cell of enteric neurotransmission, subject to neurotransmitter receptor signaling which generates functional effects on enteric neural reflexes (Seguella and Gulbransen, 2021; Thomasi and Gulbransen, 2023). The myenteric glia, present inside the myenteric plexus, has a privileged location for interaction with enteric neurons (Gabella, 2022). They establish bidirectional communication based on the release of neuroactive substances, neurotransmitters, hemichannels signaling, and neuroimmune mediators which may strongly account for enteric neuroplasticity (Thomasi and Gulbransen, 2023). Enteric glia can be activated by cholinergic signaling, the main excitatory control pathway of the ENS, to release neurotransmitters such as GABA and ATP, in addition to neuromodulators such as prostaglandins, cytokines, and trophic factors (Esposito et al., 2017; Fried et al., 2017; Delvalle et al., 2018b). Intercellular glial signaling via Connexin-43 (Cx43) is described as a mediator of neural reflexes and its absence in animal models knockouts impact colonic migrating motor complexes (McClain et al., 2014; Grubisic and Parpura, 2017). Furthermore, enteric glial activation modulates and activates enteric neural reflexes (McClain et al., 2015; Ahmadzai et al., 2021). The description of glial reactivity in the intestine of patients with PD and the early inflammatory scenario reinforces the idea that impaired glial cell activity may be associated with dysmotility manifested as constipation in PD. Abnormalities in glial signaling, decrease or loss of these cells, or even a pro-inflammatory polarization are considered possible mechanisms of gliopathy associated with constipation (Bassotti et al., 2011; Holland et al., 2021). Considering the progression of PD, GI dysfunction mediated and/or modulated by the reactive profile of enteric glia, probably reinforces peripheral pathological processes, such as dysbiosis and neuroinflammation itself.

The pain component is extremely relevant in any pathology because it impairs the patient’s quality of life and, in PD, also because it increases the frequency of other non-motor symptoms, such as depression and sleep disorders (Roversi et al., 2021). Visceral pain is triggered by the activation of nociceptors in the internal organs. Nociceptors are vast ion-channel receptor class specialists in the detection of harmful stimuli. It can be modulated by autonomic and central neural pathways, by immune mediators, and gains its perception in the CNS (Roversi et al., 2021). Among them, the TRPV channel family is commonly described in multiple GI disorders with a prevalence of the multisensory receptor TRPV1 (Du et al., 2019). This receptor is broadly expressed in the neural structures of the ENS as the mucosal layer, myenteric plexus, and mainly in the submucosal plexus (Akbar et al., 2010). The current notion about TRPV1 in the gut wall describes its expression mainly as from extrinsic innervation terminals and by intrinsic sensory neurons directly connecting ENS and CNS in pain pathways (Matsumoto et al., 2009; Delvalle et al., 2018a). Data from patients with PD describe abdominal pain related to GI dysfunction. In accordance with primary constipation, pain commonly precedes PD motor symptoms over many years, and it is not necessarily related to the severity of motor symptoms (Ha and Jankovic, 2012). Likely, disturbed GI immunity at the beginning of PD pathology is another contributor to visceral hypersensitivity in the prodromal phase of PD since several pain-sensitizing ligands from immune cells can activate nociceptors, as TRPV1 (Roversi et al., 2021). Considering the early intestinal neuroinflammatory component and constipation, it is very likely that PD patients experience both abnormal stimulations in the GI wall that sensitize nociception fibers and altered transduction and perception of pain, at the peripheral or central levels (Wong et al., 2020).

In the giant GI surface with intrinsic and extrinsic innervations closing signaling, pathological mechanisms from ENS are likely to operate underlying GI dysfunction-related pain during PD. Using the 6-OHDA animal model of PD, Pellegrini and collaborators showed increased tachykininergic enteric neurotransmission in the colonic ENS after neurodegeneration induction. In addition, inflammation with enteric glia overexpression of GFAP and increased substance P labeling were both detected in the large intestine (Pellegrini et al., 2016b). Tachykinins, as substance P and neurokinins, and their neurokinin receptors (NKR) are broadly found in the GI tract, and they have been described as neuroglial mediators during intestinal inflammation and pain (Corsetti et al., 2015; Delvalle et al., 2018a). Neurokinin A (NKA) is shown to drive enteric neuroglial responses evoked primarily by neurons that recruit surrounding enteric glia through purinergic and Cx43 pathways – known inflammatory-related mechanisms (Delvalle et al., 2018a; Grubisic et al., 2020). Colonic TRPV1+ varicosities express functional NK2Rs, respond to NKA and, prevent glial reactivity when blocked during inflammation (Delvalle et al., 2018a). As seen in the colitis animal model, NK2R blockade also avoided muscle contractibility dysfunction, demonstrating that TRPV1+ neurons with functional NK signaling are associated with reactive glial and dysmotility during inflammation. In a late report, using transgenic animals expressing genetically encoded calcium indicators in TRPV1+ fibers, Cx43 hemichannels were again implicated during intestinal inflammation as a sensitizer mechanism of colonic nociceptors (Grubisic et al., 2020). In addition, specific enteric glia activation through Designer Receptors Exclusively Activated by Designer Drugs, not only modulates visceromotor responses but also potentiates nociceptors activation in sensory neurons in a pro-inflammatory context (Morales-Soto and Gulbransen, 2020). Furthermore, glial Cx43 has been described as a potent modulator of abdominal hypersensitivity during inflammation by modulating macrophage phenotype in the neuromuscular compartment (Grubisic et al., 2020), a region that undergoes profound neurochemical and inflammatory alterations in animal models of PD (Fornai et al., 2016; Pellegrini et al., 2016b; Thomasi et al., 2022). Evaluations on irritable bowel syndrome gut biopsies also point out that both glial S100B and Cx43 play a functional role in the frequency and intensity of pain reported by patients which may count with modified glial responsiveness to purines, a fundamental neuroglial communication mechanism (Lilli et al., 2018).

Animals submitted to nigrostriatal neurodegeneration using 6-OHDA display increased central expression of TRPV1 associated with thermal and mechanical hyperalgesia (Li et al., 2020). Interestingly, in the CNS of animal models of PD, TRPV1 signaling has been linked with neuronal restoration and oxidative stress amelioration, and these processes are associated with glial activation or glial mechanisms (Nam et al., 2015; Chung et al., 2017). No research has been published investigating enteric TRPV1 signaling in the multiple aspects this receptor could be involved in during PD, mainly intestinal inflammation and abdominal pain. Moreover, despite the extensive report about glial roles in the central neuroplasticity in pain pathways, and the ability of the central glial network to convey signals intestine-derived (Gazerani, 2021; He et al., 2021; Hiraga et al., 2022; Wu et al., 2023), we have few descriptions of enteric glia on the gut-brain axis pain signaling during PD despite their likely contribution. In an elegant report, Lucarini and colleagues demonstrated that enteric glial impairment using glial poisoning before colitis induction was enough to contain visceral hypersensitivity and inflammation as well (Lucarini et al., 2021). When enteric glia were inhibited in this scenario, there was also reduced overexpression of S100B and TRPV1 at different points along the gut-brain axis, from the myenteric plexus, gaining the dorsal root ganglia and reaching the periaqueductal gray area – the latter being a relevant brain area for pain perception (Lucarini et al., 2021). Given the potential of enteric glia to act as an (I) local modulator, sensitizing nociceptors, (II) their ability to signal and recruit glial networks in the gut-brain axis, (III) the description of their pathological state in the ENS of patients with PD, enteric glia may be a novel target with innovative potential for the development of therapies related to pain during PD.

5. Could enteric glial cells be a therapeutic target for Parkinson’s disease treatment?

The ENS is a target for the treatment of several GI disorders, such as achalasia, slow transit constipation, and gastroparesis (Fleming et al., 2020). Many of these conditions are related to DGBIs. However, there is no current effective treatment for PD-related GI disorders. Likewise, whether therapeutic strategies addressing the gut could also improve CNS-related PD symptoms is unknown. Due to its central role in GI and gut-brain homeostasis, enteric glial cells have emerged as a potential target for DGBI therapy.

Despite drugs or therapies specifically designed to modulate enteric glial cells do not exist, ongoing studies aim to explore enteric glial mechanisms to improve gut functioning (Gulbransen and Christofi, 2018). Indeed, such mechanisms are affected by some available therapy strategies for functional bowel disorders (Seguella and Gulbransen, 2021). Among the main candidates, intracellular glial Ca2+ signaling could be highlighted, which influences gut motility and secretion. Downstream glial intracellular Ca2+ responses involve Cx43 hemichannels, which also engage in glial-mediated inflammatory activity by releasing ATP and activating P2X7 and pannexin-1 receptors (Gulbransen and Christofi, 2018). Thus, targeting Cx43 could improve both neuroinflammation and dysmotility. Some other glial mediators involved in immunological signaling that are hypothesized to contribute to gut pathological processes could also be targeted by new therapeutic strategies, such as IL-1R, TLR4, RAGE and peroxisome proliferator-activated receptor alpha (PPAR-α; Esposito et al., 2007, 2014; Stoffels et al., 2014).

Enteric glia are a predominant source of GDNF, a trophic factor that has pivotal protective effects on ENS and IEB (Meir et al., 2021). GDNF levels are altered in disorders characterized by GI neuroinflammation, such as IBDs, Hirschsprung disease and PD (Ochoa-Cortes et al., 2016; Manfredsson et al., 2020) and it has been shown to improve colonic functions and induce enteric neurogenesis in Hirschsprung disease mouse models (Soret et al., 2020). GDNF-based therapy is currently being discussed as an alternative treatment for PD. Although successfully tested in preclinical models, it has failed to reproduce motor symptom amelioration in patients (Marks et al., 2008; Merola et al., 2020). Still, researchers in the field believe the failure is mainly related to inappropriate delivery rather than GDNF ineffectiveness (Manfredsson et al., 2020). Nonetheless, all studies focus on CNS modulation and whether and how it would affect ENS and gut function is unknown. Given the previously described changes in GDNF gut levels, neuroinflammation and increased IEB permeability during PD, it is very likely that a GDNF-based therapy would impact PD GI symptoms by modulating enteric glia function toward an anti-inflammatory profile, among other gut mechanisms (Pellegrini et al., 2020; Thomasi et al., 2022).

More recently, some gut-oriented therapies have been proposed for treating PD symptoms, of which the use of nutraceuticals and the modulation of gut microbiota could be highlighted as the most promising strategies. Nutraceutical is a substance or part of a food that is beneficial for health and can be used for medical purposes, including disease prevention and treatment. Although available data is scarce, some studies suggest these compounds might have antioxidant, anti-inflammatory, or modulatory effects on enteric glial cells. For example, compounds like palmitoylethanolamide, cannabidiol and berberine can reduce gut inflammation and nociception in both IBD models and patients (López-Gómez et al., 2021). For the first two, these effects were described to occur through the activation of PPARs in enteric glial cells (Filippis et al., 2011; Sarnelli et al., 2018). The use of nutraceuticals that modulate glial cells as a therapeutic strategy was also investigated in a neurotoxin-based model of PD with peripheral induction. Antioxidant coffee compounds prevented nigrostriatal and enteric neurodegeneration by enhancing the antioxidant properties of glial cells after rotenone subcutaneous administration (Miyazaki et al., 2019). However, the study did not evaluate whether it could also improve gut symptoms, a known feature of the rotenone PD models. Given that inflammation is one of the pathological events underlying PD GI dysfunction, nutraceutical compounds that can target the enteric glia should be considered in future studies as a potential therapy for PD-related gut dysfunction.

The enteric glia can also be indirectly targeted as a therapeutic strategy by modulating the gut microbiota. The gut microbiota can be modulated in many ways, including nutraceuticals such as probiotics. Other strategies include prebiotics, antibiotics, and fecal microbiota transplantation (FMT), which might affect glial mechanisms in the gut (Xu et al., 2022). For example, the administration of Bifidobacterium bifidum in a model of intestinal inflammation could reduce gut inflammation by regulating the release of pro-inflammatory molecules by the enteric glia (Yang et al., 2020). Gut microbiota modulation has been intensively investigated as a therapy for PD, with some successful tests in both human and preclinical studies (Xu et al., 2022; DuPont et al., 2023). In a neurotoxin model of PD, FMT reduced neuroinflammation by decreasing both microglia and astrocyte activation, as well as TLR4/TNF-a signaling pathway (Sun et al., 2018; Zhao et al., 2021). The benefits of the treatment were attributed to the increase in the presence of SCFAs, however, GI pathophysiology was not addressed. Likewise, sodium butyrate was further reported to restore IEB integrity, reduce systemic inflammation and improve motor behavior in the same PD model (Xu et al., 2022). However, whether the mechanisms of proposed microbiota-based PD therapies involve enteric glia is still unknown, yet likely. Despite promising, therapies targeting the gut microbiota still have many challenges to be established as a reliable treatment for PD symptoms, including the great variability of microbiota among patients, variability of diets, which also influences microbiota composition, and a better understanding of the underlying mechanisms. Further studies could address the effects of microbiota modulation on the enteric glia during PD and how it could relate to the improvement of both GI and motor dysfunction.

6. Conclusion

The gut-brain axis sensitization in PD and enteric glia roles in this scenario are summarized in Figure 1. PD is a complex neurodegenerative disorder involving significant gut-brain axis dysregulation. Interaction between intestinal, neural, and immunological components are key factors in the pathology of PD. PD-related GI symptoms, including constipation and abdominal pain, are emerging as early indicators of the disease, and the involvement of enteric glial cells in the pathogenesis of these symptoms presents them as potential therapeutic targets. Currently, there are no effective treatments that target both PD GI and motor symptoms, despite significant research efforts. Considering the complex bidirectional interactions between the gut and the brain, enteric glia represent a promising target for therapeutic intervention in PD because of their immunomodulatory ability. Glia-oriented therapies could provide anti-inflammatory and antioxidant outcomes and trophic responses as well. By focusing on modulating these cells, therapeutical strategies that address both the GI and central aspects of the disease in an early period may impact the pathologic course, symptoms development, and quality of life of patients with PD.

www.frontiersin.org

Figure 1. Enteric glia, gut dysfunction and neuroimmune mechanisms to gut-brain axis sensitization. On the left, are the classic pre-motor and non-motor symptoms of the prodromal phase of PD. Both glial reactivity and inflammation are strongly implicated in the neurodegenerative process and contribute to pathology progression. Dysbiosis adds to this scenario as another pro-inflammatory element. (A) Enteric glia phenotype and inflammatory signature verified in biopsy samples from PD patients and PD animal models. (B) The condition of leaky gut is evidenced by the disruption of the IEB, given the alteration of the tight junction, thus promoting an increase in intestinal permeability—which should reinforce, reciprocally, the intestinal dysbiosis observed during PD. Subsequent immune activation is one of the gut-brain axis signaling pathways. (C) Exposure to bacterial bioproducts as well as the reduction of microbe-derived beneficial factors (such as SCFA) to the nervous system, reinforce the pro-inflammatory condition and modify the axis based on signaling by biofilm and its derivatives. (D) Enteric glial mechanisms are recognized in PD and/or IBD associated with pro-inflammatory action, dysmotility, and visceral pain.

Author contributions

BT: Conceptualization, Supervision, Writing – original draft, Writing – review & editing. LV: Writing – original draft, Writing – review & editing. MR: Writing – review & editing. MG: Writing – review & editing. IF: Writing – review & editing. AT-G: Conceptualization, Funding acquisition, Supervision, Writing – original draft, Writing – review & editing.

Funding

The author(s) declare financial support was received for the research, authorship, and/or publication of this article. This paper and associated scholarships were supported by the following Brazilian foundations: Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES), Brazil—Finance Code 001—MR received CAPES fellowship; Pró-Reitoria de Pesquisa, Pós-graduação e Inovação (PROPPI), Brazil—partial financial support to submission; and Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPq), Brazil—Grant number: IC220397—MG received CNPq fellowship.

Acknowledgments

We thank the Neuroscience Program from Universidade Federal Fluminense, especially the professors Dr. Adriana da Cunha Faria Melibeu, Dr. Adriana Silva, Dr. Lucianne Fragel, and Dr. Marcelo Cossenza.

Conflict of interest

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References



Source link